Active Ingredient(s): Elosulfase Alfa
FDA Approved: * February 14, 2014
Pharm Company: * BIOMARIN PHARM

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vimizim Overview

Morquio syndrome, also known as Mucopolysaccharidosis Type IV (MPS IV), is a rare metabolic disorder in which the body cannot process certain types of sugar molecules called glycosaminoglycans (AKA GAGs, or mucopolysaccharides). In Morquio syndrome, the specific GAG which builds up in the body is called keratan sulfate. This birth defect, which is autosomal recessive, is a type of lysosomal storage disorder. The buildup of GAGs in different parts of the body causes symptoms in many different ...

Read more Vimizim Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Vimizim Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Elosulfase Alfa
  • Injection: 5mg/5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vimizim: (1 result)

Sorted by National Drug Code
  • 68135-100 Vimizim 5 mg/5ml Intravenous Injection, Solution, Concentrate by Biomarin Pharmaceutical Inc.

Other drugs which contain Elosulfase Alfa or a similar ingredient: (1 result)